Investigational Site Number: 2500002

Lille 59037

3 studies enrolling now · 8 studies all time

What they study most

Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Asthma, Chronic Rhinosinusitis With Nasal Polyps, Chronic Spontaneous Urticaria, Hemophilia, Neurodermatitis, Plasma Cell Myeloma Refractory, Ulcerative Colitis

Studies at this site

• Isatuximab in Combination With Novel Agents in RRMM - Master Protocol — Recruiting now
• A Study to Investigate the Efficacy and Safety of SAR442970 in Adult Participants With Ulcerative Colitis — Recruiting now
• A Study to Investigate the Safety and Efficacy of SAR446523 Injected Subcutaneously in Adult Participants With Relapsed/Refractory Myeloma — Recruiting now
• A Study to Test a Medicine (Fitusiran) Injected Under the Skin for Preventing Bleeding Episodes in Male Adolescent or Adult Participants With Severe Hemophilia — Running, not enrolling
• EValuating trEatment RESponses of Dupilumab Versus Omalizumab in Type 2 Patients — Completed
• Study of Dupilumab for the Treatment of Patients With Prurigo Nodularis, Inadequately Controlled on Topical Prescription Therapies or When Those Therapies Are Not Advisable (PRIME2) — Completed
• Isatuximab in Combination With Chemotherapy in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia — Stopped early
• Dupilumab for the Treatment of Chronic Spontaneous Urticaria in Patients Who Remain Symptomatic Despite the Use of H1 Antihistamine and Who Are naïve to, Intolerant of, or Incomplete Responders to Omalizumab (LIBERTY-CSU CUPID) — Completed